VVMF - Viral Vector Manufacturing Facility
VVMF is a newly established (2024) viral vector manufacturing facility based in Westmead, NSW, Australia, with approximately 40 employees. It operates in the contract manufacturing segment serving gene therapy and cell therapy developers, though no product, customer, or commercial details are publicly disclosed.
- Company typePrivate
- Founded-
- Headquarters—
- Headcount11–50
- GTM typeB2B
- OfferingServices
What VVMF - Viral Vector Manufacturing Facility does
VVMF — Viral Vector Manufacturing Facility — is an Australian-headquartered manufacturing organization based in Westmead, New South Wales, founded in 2024 with a current headcount of approximately 40 employees. Based on the company name, it operates in the contract development and manufacturing (CDMO) segment of viral vector production, a critical input supply chain for gene therapy, cell therapy, and vaccine developers. The facility's location in Westmead, a major Sydney biomedical precinct anchored by Westmead Hospital and the Westmead Health and Innovation Precinct, suggests access to clinical research customers and workforce talent in the Australian life sciences cluster.
No substantive information about the company's core technology, production platforms, capacity, regulatory certifications (e.g., TGA GMP licensing), or specific product/service offerings is currently disclosed through public sources. The company's website (vvmf.com.au) presents only a loading/verification page with no accessible product, technology, or capability content. No pricing models, customer segments, partnerships, leadership team, or funding history are publicly available in the source data reviewed.
The business model cannot be characterized from available data. In the CDMO sector more broadly, revenue is typically generated through fee-for-service contracts, milestone-based development payments, and per-batch or per-dose manufacturing charges — but no such pricing detail, contract structure, or go-to-market signals are available for VVMF. The absence of disclosed customers, revenue figures, or strategic partnerships means the company's commercial traction cannot currently be assessed.
VVMF - Viral Vector Manufacturing Facility firmographics
Firmographics- Name
- VVMF - Viral Vector Manufacturing Facility
- Website
- https://vvmf.com.au
- Company type
- Private
- Headcount range
- 11–50 employees
- Short description
- VVMF is a newly established (2024) viral vector manufacturing facility based in Westmead, NSW, Australia, with approximately 40 employees. It operates in the contract manufacturing segment serving gene therapy and cell therapy developers, though no product, customer, or commercial details are publicly disclosed.
- Ownership category
- akta.pro rank
VVMF - Viral Vector Manufacturing Facility industry classification
Industry- Product category
- Biopharmaceutical Contract Manufacturing
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD)
Keywords
VVMF - Viral Vector Manufacturing Facility business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Others
VVMF - Viral Vector Manufacturing Facility product offering
Product offeringCore offering
VVMF is a contract manufacturing facility that produces viral vectors for use in gene therapies, cell therapies, and vaccine development. The organization provides biotech and pharmaceutical clients with dedicated biomanufacturing capacity, process development support, and aseptic production capability at its Westmead, NSW site. Its output is physical viral vector material (drug substance and/or drug product) manufactured to pharmaceutical quality standards.
Product overview
No product information available. The source page displays a verification/loading screen with no accessible product content.
Differentiator
Problem solved
Functional benefit
Companies that use VVMF - Viral Vector Manufacturing Facility
Customer profileIdeal customer profiles1 record
VVMF - Viral Vector Manufacturing Facility technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
VVMF - Viral Vector Manufacturing Facility partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
VVMF - Viral Vector Manufacturing Facility competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Global pharmaceutical CDMO with dedicated viral vector and cell-and-gene therapy manufacturing capacity across multiple sites. Directly comparable as the dominant incumbent VVMF would compete against in viral vector services.
- Charles River Laboratories: Provides viral vector and cell therapy CDMO services (Cognate Bio, Retrogenix legacy) alongside broader preclinical and biologics capabilities. Comparable as a multi-service CDMO with material viral vector exposure.
- Catalent (Novo Holdings): Major CDMO with viral vector and gene therapy manufacturing services (formerly Paragon) and global biomanufacturing footprint. Comparable as a scaled incumbent offering overlapping viral vector capabilities.
- WuXi Advanced Therapies (WuXi AppTec): Provides viral vector and cell therapy manufacturing services within WuXi AppTec's global CRDMO platform. Comparable as a large Asia-Pacific-adjacent CDMO with viral vector capabilities.
- AGC Biologics: Global CDMO offering viral vector and cell therapy manufacturing services from European and US facilities. Comparable as a scaled CDMO with overlapping viral vector and gene therapy manufacturing capabilities.
- SK pharmteco / Center for Breakthrough Medicines: Cell and gene therapy CDMO with substantial viral vector capacity (Center for Breakthrough Medicines). Comparable as a competing CDMO with overlapping viral vector CDMO services.
- Thermo Fisher Scientific (Patheon / Brammer Bio): Through its Patheon and Brammer Bio acquisitions, Thermo Fisher offers viral vector development and manufacturing services. Comparable as a large diversified CDMO with overlapping viral vector CDMO offerings.
Direct peers
- Genezen: US-based viral vector and lentiviral manufacturing CDMO focused on early-stage gene therapy developers. Most directly comparable pure-play peer: same service offering (viral vector manufacturing), targeting clinical-stage biotech customers.
- VintaBio: US-based viral vector manufacturing CDMO focused on AAV and lentiviral production for gene therapy developers. Highly comparable as a pure-play viral vector CDMO directly overlapping with VVMF's service scope.
Others
- Cytiva (Danaher): Supplies bioprocess equipment, single-use technologies, and viral vector manufacturing solutions to CDMOs like VVMF. Comparable as a key enabler/supplier into the viral vector manufacturing infrastructure rather than a direct competitor.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
VVMF - Viral Vector Manufacturing Facility social profiles
Digital presenceVVMF - Viral Vector Manufacturing Facility financial estimates
Financial estimateRevenue estimate
Valuation estimate
VVMF - Viral Vector Manufacturing Facility leadership team
Management profileNumber of profiles
VVMF - Viral Vector Manufacturing Facility funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VVMF - Viral Vector Manufacturing Facility M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VVMF - Viral Vector Manufacturing Facility
What does VVMF - Viral Vector Manufacturing Facility do?
VVMF is a contract manufacturing facility that produces viral vectors for use in gene therapies, cell therapies, and vaccine development. The organization provides biotech and pharmaceutical clients with dedicated biomanufacturing capacity, process development support, and aseptic production capability at its Westmead, NSW site. Its output is physical viral vector material (drug substance and/or drug product) manufactured to pharmaceutical quality standards.
When was VVMF - Viral Vector Manufacturing Facility founded?
VVMF - Viral Vector Manufacturing Facility was founded in -1. It employs 11 to 50 people.
Who are VVMF - Viral Vector Manufacturing Facility's main competitors?
Broad incumbents on record are Lonza Group, Charles River Laboratories, Catalent (Novo Holdings), WuXi Advanced Therapies (WuXi AppTec), AGC Biologics, SK pharmteco / Center for Breakthrough Medicines and Thermo Fisher Scientific (Patheon / Brammer Bio). Direct peers are Genezen and VintaBio. Cytiva (Danaher) is listed as an others.
Does VVMF - Viral Vector Manufacturing Facility have an API?
No public API is recorded for VVMF - Viral Vector Manufacturing Facility.
What industry is VVMF - Viral Vector Manufacturing Facility in?
VVMF - Viral Vector Manufacturing Facility's product category is Biopharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAAAKAD, Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral). Its NAICS code is 5417 and its SIC code is 8731.